InsidersTradesSigma
Follow the Caladrius Biosciences, INC. share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Caladrius Biosciences, INC. has recorded 31 insider filings. The latest transaction was filed on 2 September 2022 (Attribution). Among the most active insiders: Mazzo David J. The full history is free.
31
Insider Decl.
n/a
Thresholds
€26,773
1 ops.
Buy Volume
n/a
n/a
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 September 2022
Declarations31 total
58,000 shares@ US$0.50100.0% of flowCommon StockSEC:0001879231-22-000006:0
150,000 shares@ US$0.5089.2% of flowCommon StockSEC:0001334549-22-000007:0
2,563 shares@ US$0.806350.0% of flowCommon StockSEC:0001891257-22-000004:0
6,471 shares@ US$0.806350.0% of flowCommon StockSEC:0001334549-22-000004:0
401,000 shares0Common StockSEC:0001334549-22-000002:0
65,430 shares0Common StockSEC:0001192621-22-000002:0
65,430 shares0Common StockSEC:0001573785-22-000002:0
65,430 shares0Common StockSEC:0001284500-22-000003:0
65,430 shares0Common StockSEC:0001373585-22-000002:0
64,500 shares0Common StockSEC:0001879231-22-000002:0
65,430 shares0Common StockSEC:0001741455-22-000002:0
65,430 shares0Common StockSEC:0001078274-22-000002:0
129,000 shares0Common StockSEC:0001891257-22-000002:0
65,430 shares0Common StockSEC:0001593283-22-000002:0
33,785 shares@ US$0.893650.0% of flowCommon StockSEC:0001078274-21-000006:0
Canonical exit: 8 Mar 2022 (T+90)
312,500 shares0Common StockSEC:0001879231-21-000006:0
9,000 sharesCommon StockSEC:0001144204-16-077386:0
10,000 sharesCommon StockSEC:0001144204-16-077384:0
76,000 sharesCommon StockSEC:0001144204-16-077385:0
8,032 sharesCommon StockSEC:0001144204-16-077385:1
9,000 sharesCommon StockSEC:0001144204-16-077387:0
212,800 sharesCommon StockSEC:0001144204-16-077388:0
21,094 sharesCommon StockSEC:0001144204-16-077388:1
9,000 sharesCommon StockSEC:0001144204-16-077389:0
76,000 sharesCommon StockSEC:0001144204-16-077390:0
25 of 31 declarations
关于 Caladrius Biosciences, INC.
Caladrius Biosciences, Inc.（股票代码：CLBS）是一家与纳斯达克市场相关的美国生物制药公司。对于讲法语的投资者而言，它应被视为一家专注于细胞疗法和再生医学的临床阶段生物技术公司，而非成熟的、产生现金的制药平台。历史上，该公司围绕旨在逆转或显著改变严重疾病进展的创新细胞疗法建立了其特许经营权，重点关注心血管和其他慢性适应症。该公司总部在SEC和纳斯达克材料中披露为新泽西州巴斯金里奇，使其位于美国核心生物技术集群之一。（[nasdaq.com](https://www.nasdaq.com/press-release/caladrius-biosciences-closes-%245.0-million-registered-direct-offering-priced-at-the?utm_source=openai)) 在业务线方面，Caladrius专注于CD34+细胞治疗候选药物以及具有显著未满足医疗需求的适应症。SEC文件和公司披露提及了冠状微血管功能障碍（CMD）、危重肢体缺血（CLI）、伯格氏病、1型糖尿病和糖尿病肾病的项目。例如，用于CMD的XOWNA/CLBS16，用于CLI的HONEDRA/CLBS12，以及用于糖尿病肾病的CLBS201。这使得该公司具有明确差异化的科学特征，但也使其高度依赖临床结果、监管进展和资本获取。（[sec.gov](https://www.sec.gov/Archives/edgar/data/320017/000114036122023089/R27.htm?utm_source=openai)) 从竞争角度来看，Caladrius处于一个科学壁垒高但细胞疗法和再生医学开发商之间竞争激烈的利基市场。其投资案例历来取决于临床数据质量、有利监管认定的潜力以及公司为漫长开发周期提供资金的能力。纳斯达克新闻稿随着时间的推移显示了反复的股权融资和其他筹资行动，突显了其开发模式的资金密集性，这对于小型生物技术发行人来说很常见。（[nasdaq.com](https://www.nasdaq.com/press-release/caladrius-biosciences-closes-%245.0-million-registered-direct-offering-priced-at-the?utm_source=openai)) 最近的里程碑对于解读当前的内部人备案至关重要。搜索结果中可用的最新SEC文本仍然描述了一个以XOWNA/CLBS16、HONEDRA/CLBS12和CLBS201为核心的投资组合，以及正在进行的临床工作。然而，Caladrius还在2022年宣布与Cend Therapeutics达成合并协议，成立Lisata Therapeutics，这实质性地改变了公司的企业故事。因此，分析CLBS Form 4内部人交易的投资者应在备案时核实确切的法律实体和上市状态，因为历史上的Caladrius叙述可能与当前上市公司结构不完全匹配。（[sec.gov](https://www.sec.gov/Archives/edgar/data/320017/000032001722000064/a425rochepressrelease20220.htm?utm_source=openai))
